Is GeneDx Holdings Stock a Good Investment?
GeneDx Holdings Investment Advice | WGSWW |
- Examine GeneDx Holdings' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research GeneDx Holdings' leadership team and their track record. Good management can help GeneDx Holdings navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Health Care Technology space and any emerging trends that could impact GeneDx Holdings' business and its evolving consumer preferences.
- Compare GeneDx Holdings' performance and market position to its competitors. Analyze how GeneDx Holdings is positioned in terms of product offerings, innovation, and market share.
- Check if GeneDx Holdings pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about GeneDx Holdings' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in GeneDx Holdings Corp stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if GeneDx Holdings Corp is a good investment.
Sell | Buy |
Cautious Hold
Market Performance | Solid | Details | |
Volatility | Out of control | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Fairly Valued | Details | |
Odds Of Distress | Above Average | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Not Available | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine GeneDx Holdings Stock
Researching GeneDx Holdings' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The company had not issued any dividends in recent years.
To determine if GeneDx Holdings is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding GeneDx Holdings' research are outlined below:
| GeneDx Holdings Corp is way too risky over 90 days horizon | |
| GeneDx Holdings Corp has some characteristics of a very speculative penny stock | |
| GeneDx Holdings Corp appears to be risky and price may revert if volatility continues | |
| GeneDx Holdings Corp has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 202.57 M. Net Loss for the year was (175.77 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| GeneDx Holdings generates negative cash flow from operations | |
| GeneDx Holdings Corp has a frail financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: Genedx director Ryan sells shares worth 3.3 million - Investing.com |
GeneDx Holdings' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.58) | (0.61) | |
| Return On Capital Employed | (0.39) | (0.41) | |
| Return On Assets | (0.37) | (0.39) | |
| Return On Equity | (0.77) | (0.81) |
Determining GeneDx Holdings' profitability involves analyzing its financial statements and using various financial metrics to determine if GeneDx Holdings is a good buy. For example, gross profit margin measures GeneDx Holdings' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of GeneDx Holdings' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in GeneDx Holdings' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of GeneDx Holdings Corp. Check GeneDx Holdings' Beneish M Score to see the likelihood of GeneDx Holdings' management manipulating its earnings.
Evaluate GeneDx Holdings' management efficiency
The company has return on total asset (ROA) of (0.0827) % which means that it has lost $0.0827 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.364) %, meaning that it generated substantial loss on money invested by shareholders. GeneDx Holdings' management efficiency ratios could be used to measure how well GeneDx Holdings manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.61 in 2024. Return On Capital Employed is likely to drop to -0.41 in 2024. At this time, GeneDx Holdings' Total Assets are fairly stable compared to the past year. Non Currrent Assets Other is likely to climb to about 61.3 M in 2024, whereas Intangible Assets are likely to drop slightly above 143.7 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 9.38 | 9.85 | |
| Tangible Book Value Per Share | 2.28 | 2.39 | |
| Enterprise Value Over EBITDA | (0.64) | (0.61) | |
| Price Book Value Ratio | 0.29 | 0.52 | |
| Enterprise Value Multiple | (0.64) | (0.61) | |
| Price Fair Value | 0.29 | 0.52 | |
| Enterprise Value | 86.9 M | 91.3 M |
Effective management at GeneDx Holdings has been a driving force behind its market achievements. We assess the correlation between management practices and financial success to determine the stock's value.
Beta 2.18 |
Basic technical analysis of GeneDx Stock
As of the 28th of November, GeneDx Holdings retains the Downside Deviation of 7.57, market risk adjusted performance of 2.25, and Risk Adjusted Performance of 0.236. Concerning fundamental indicators, the technical analysis model lets you check existing technical drivers of GeneDx Holdings Corp, as well as the relationship between them. Please check out GeneDx Holdings Corp treynor ratio, as well as the relationship between the potential upside and expected short fall to decide if GeneDx Holdings is priced fairly, providing market reflects its last-minute price of 0.14 per share. As GeneDx Holdings Corp appears to be a penny stock we also urge to confirm its total risk alpha numbers.Understand GeneDx Holdings' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing GeneDx Holdings' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.236 | |||
| Market Risk Adjusted Performance | 2.25 | |||
| Mean Deviation | 8.31 | |||
| Semi Deviation | 5.53 | |||
| Downside Deviation | 7.57 | |||
| Coefficient Of Variation | 337.32 | |||
| Standard Deviation | 12.11 | |||
| Variance | 146.56 | |||
| Information Ratio | 0.2857 | |||
| Jensen Alpha | 3.39 | |||
| Total Risk Alpha | 1.67 | |||
| Sortino Ratio | 0.4567 | |||
| Treynor Ratio | 2.24 | |||
| Maximum Drawdown | 69.2 | |||
| Value At Risk | (11.11) | |||
| Potential Upside | 27.78 | |||
| Downside Variance | 57.35 | |||
| Semi Variance | 30.55 | |||
| Expected Short fall | (12.01) | |||
| Skewness | 1.52 | |||
| Kurtosis | 3.31 |
| Risk Adjusted Performance | 0.236 | |||
| Market Risk Adjusted Performance | 2.25 | |||
| Mean Deviation | 8.31 | |||
| Semi Deviation | 5.53 | |||
| Downside Deviation | 7.57 | |||
| Coefficient Of Variation | 337.32 | |||
| Standard Deviation | 12.11 | |||
| Variance | 146.56 | |||
| Information Ratio | 0.2857 | |||
| Jensen Alpha | 3.39 | |||
| Total Risk Alpha | 1.67 | |||
| Sortino Ratio | 0.4567 | |||
| Treynor Ratio | 2.24 | |||
| Maximum Drawdown | 69.2 | |||
| Value At Risk | (11.11) | |||
| Potential Upside | 27.78 | |||
| Downside Variance | 57.35 | |||
| Semi Variance | 30.55 | |||
| Expected Short fall | (12.01) | |||
| Skewness | 1.52 | |||
| Kurtosis | 3.31 |
Consider GeneDx Holdings' intraday indicators
GeneDx Holdings intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of GeneDx Holdings stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
GeneDx Holdings time-series forecasting models is one of many GeneDx Holdings' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary GeneDx Holdings' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
GeneDx Stock media impact
Far too much social signal, news, headlines, and media speculation about GeneDx Holdings that are available to investors today. That information is available publicly through GeneDx media outlets and privately through word of mouth or via GeneDx internal channels. However, regardless of the origin, that massive amount of GeneDx data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of GeneDx Holdings news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of GeneDx Holdings relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to GeneDx Holdings' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive GeneDx Holdings alpha.
GeneDx Holdings Corporate Management
| Daniel JD | Secretary | Profile | |
| Britt Johnson | Head Affairs | Profile | |
| Jami Biliboaca | Head Strategy | Profile | |
| Eric Olivares | Chief Officer | Profile | |
| Tricia Truehart | Head Relations | Profile | |
| MBA JD | General Counsel | Profile |
Already Invested in GeneDx Holdings Corp?
The danger of trading GeneDx Holdings Corp is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of GeneDx Holdings is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than GeneDx Holdings. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile GeneDx Holdings Corp is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for GeneDx Stock Analysis
When running GeneDx Holdings' price analysis, check to measure GeneDx Holdings' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GeneDx Holdings is operating at the current time. Most of GeneDx Holdings' value examination focuses on studying past and present price action to predict the probability of GeneDx Holdings' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GeneDx Holdings' price. Additionally, you may evaluate how the addition of GeneDx Holdings to your portfolios can decrease your overall portfolio volatility.